$2.30 -0.04 (-1.71%)
11/6/2009 3:59 PM

Corcept Therapeutics, Inc. (CORT)

CAPS Rating: 1 out of 5

A pharmaceutical company which is engaged in the development of drugs for the treatment of severe psychiatric and metabolic diseases.

Current Price $2.30 Mkt Cap $114.46M
Open $2.28 P/E Ratio 0.00
Prev. Close $2.34 Div. (Yield) N/A (N/A)
Daily Range $2.20 - $2.40 Volume 27,978
52-Wk Range $0.73 - $3.10 Avg. Daily Vol. 88,000

CORT News and Commentary

Related News and Articles

Caps

How do you think CORT will perform vs the S&P 500?

Add Stock to Watchlist

All Members

35 Outperform
13 Underperform
 

All-Star Members

5 Outperform
5 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top CORT Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Top Bull Pitch

There are no pitches that meet the Top Bull criteria. Explain

If this upsets you, start recommending pitches below!

zzlangerhans (99.36)
Submitted September 11, 2007

I hated this stock at 1 in April. I hated it at 2.5 in July. And now I hate it at 5. But now I finally have the privilege to thumbs down it. Corlux used to be a depresison drug, before it failed multiple phase III trials. Recently it became a… More

1 Comment | Reply | Report this Post
CORT VS S&P 500 (SPY)

Recent Community Commentary

Read the most recent pitches from members about CORT.

Recs

0
Member Avatar zzlangerhans (99.36) Submitted: 11/2/2009 11:46:41 AM : Underperform Start Price: $2.19 CORT Score: -2.82

Another inexplicable rise back up over the 100M threshold after a dilutive financing to fund yet another doomed phase III trial. God only knows how many points I can lose on this pick but some time in 2010 the Cushing's syndrome trial will be a failure.

Report this Post 0 Comments | Reply | Permalink

Recs

0
Member Avatar NoDoughBro (72.92) Submitted: 10/21/2009 11:39:43 PM : Outperform Start Price: $2.33 CORT Score: -2.68

Gimme drugs...gimme drugs.

Report this Post 0 Comments | Reply | Permalink

Recs

0
Member Avatar tiobueno (97.38) Submitted: 4/4/2008 12:29:13 PM : Outperform Start Price: $3.56 CORT Score: -16.22

March 27, 2008 12:44 PM EDT

Corcept Therapeutics Inc. (Nasdaq: CORT) Director, Joseph Cook, bought 176,522 on 3/25 at $2.77, bringing his stake to 1,656,360 shares. In addition, Director, David Mahoney, bought 70,609 shares on 3/25 at $2.77, bringing his stake to 636,547 shares.

Corcept Therapeutics Incorporated develops drugs for the treatment of severe psychiatric and metabolic diseases. [LJ]

Report this Post 0 Comments | Reply | Permalink
View All 8 Pitches »

Leaderboard

Find the members with the highest scoring picks in CORT.

Score Leader

zzlangerhans

zzlangerhans (99.36) Score: +78.99

I fought tooth and nail for this spot and I'm not planning to let go. My fourth winning pick on Corcept so far and I'll be reversing before long.

Top
Pick 		Member Name Member
Rating 		Start
Date 		Call Time
Frame 		Start
Price 		Stock
Gain 		S&P
Gain 		Score Commentary
GunnarVagotis 96.45 9/11/2007 Underperform 3M $4.74 -51.47% -23.59% +27.88 1 Comment
beugster 27.29 4/3/2008 Underperform 3W $3.80 -39.47% -18.31% +21.16
ugrmdclr < 20 7/21/2008 Outperform NS $2.15 +6.98% -12.62% +19.60
Jgleason78 86.06 4/2/2008 7/24/2008 Underperform 3M $3.74 -38.50% -19.13% +19.38
Stoxter 59.06 10/15/2007 Underperform 1Y $4.18 -44.98% -28.17% +16.80
jcook79 97.68 8/11/2008 Outperform NS $2.30 0% -15.29% +15.29
jlcable 25.41 3/31/2008 Underperform 3Y $3.25 -29.23% -15.38% +13.85
MoscowBear 66.62 9/11/2007 Underperform NS $3.58 -35.75% -23.26% +12.49
StoxInvestor 42.06 10/26/2007 Underperform 3W $3.67 -37.33% -26.62% +10.71
colddrink73 89.16 10/22/2009 Underperform 5Y $2.54 -9.45% -1.07% +8.38
View Complete Scorecard »

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Member Name Member
Rating		 Start
Date		 Call Time
Frame		 Start
Price		 Stock
Gain		 S&P
Gain		 Score End Date Commentary
TrackTWeisel < 20 8/15/2006 Outperform NS $3.69 -100.00% +1.93% -101.93 8/25/2006 @ $0.00

Featured Broker Partners